Fact.MR – A Market Research and Competitive Intelligence Provider: A new report by Fact.MR has estimated that combined immune deficiency market will grow at a healthy rate through 2021 and beyond.
Increasing Incidence of Combined Immune Deficiency Diseases to Boost the Demand for Gene Therapy among Hospitals over the Forecast Period
Market research conducted by Fact.MR on the combined immune deficiency (CID) market offers key insights regarding chief growth drivers and restrains that might impact the overall growth trajectory. The report showcases compelling case studies and information about CID demand outlook in terms of therapy type, diseases type, and end user. Key growth strategies adopted by top market players to improve sales are also discussed in this report.
Fact.MR – A Market Research and Competitive Intelligence Provider: A new report by Fact.MR has estimated that combined immune deficiency (CID) market will grow at a healthy rate through 2021 and beyond. Increasing cases of combined immune deficiency (CID) disorders along with increasing consumer spending on healthcare will boost the demand for CID treatments.
COVID-19 pandemic made a significant impact on the CID market. Patients suffering from immunity ailments are more susceptible to developing infectious diseases. The novel coronavirus also weakened immune system of those infected by the virus, thus leading to spike in number of CID patients seeking consistent medical help. High risk of morbidity and fatality of CID patients due to COVID-19 fueled the demand for treatments during the ongoing pandemic crisis.
The American Academy of Pediatrics reported that 1 in 2000 children and 1 in 600 households get diagnosed with primary immune deficiency every year. Rise in R&D activities aimed at identifying the faulty gene that could cause CID will accelerate gene sequencing and other drug development procedure. This will drive the market growth during the forecast period.
Request a report sample to gain comprehensive insights at
https://www.factmr.com/connectus/sample?flag=S&rep_id=5276
Genetic mutation tops the list of leading causes of immunity defects in terms of cell mediated and related parameters. With genetic mutation and defect induced CID ailments now affecting respiratory systems, gastrointestinal tracts, nervous systems, urinary tracts, and sensory organs, the demand for combined immune deficiency treatments will grow exponentially in the future.
A wide array of options including stem cell transplants, antibiotic therapy, and immunoglobulin replacement therapy are available to manage the long term symptoms of CID. Increasing investments towards treatment research will support the market growth throughout the forecast period.
“Growing research on genetic defects will influence the combined immune deficiency treatment development. Leading research institutes are focusing on studying these immunity ailments on genetic level to identify the causes and trigger points of these diseases. Investment in such projects will boost the market growth in upcoming decade", said a Fact.MR analyst.
Key Takeaways from Combined Immune Deficiency (CID) Market Research Report:
- The U.S. is forecast to lead the North America combined immune deficiency market owing to increasing cases of immunity ailments among toddlers along with presence of modern healthcare infrastructure in the country.
- Rising government investment towards research and development of affordable gene therapy and other immunity disorder treatments is expected to make India a lucrative market over the forecast period.
- China is expected to exhibit tremendous growth in combined immune deficiency market owing to increasing research and development activities to improve medical and healthcare system in the country.
- Gene therapy treatment will hold maximum market share due to increasing research investment and promising results from ongoing clinical trials.
- Wide of treatment options offered by antibody deficiency treatment will bolster the market growth over the assessment period.
Growth Drivers:
- Increasing cases of combined immune deficiencies (CID) across the globe especially among children and infants will drive demand for CID treatments over the forecast period.
- Increasing government and private funding for development of novel treatments for combined immune deficiencies will augment the market growth.
- Adoption of modern technology in gene therapy and therapeutic research for developing CID treatment will positively influence the market growth.
Key Restraints:
- Lack of awareness among consumers regarding combined immune deficiency disorders especially in developing countries will hinder the market growth.
- Shortage of funding and unavailability of proper diagnostic facilities will hamper the adoption of combined immune deficiency treatments.
- High cost of gene therapy for treating combined immune deficiency and strict regulatory policies for treatment approval will restrict the market growth.
To learn more about Combined Immune Deficiency (CID) Market, you can get in touch with our Analyst at
https://www.factmr.com/connectus/sample?flag=RM&rep_id=5276
Competitive Landscape
According to Fact.MR, Baxter International Inc., LFB S.A., Biotest AG, Shire Plc, Grifols S.A. are identified as top market players operating in combined immune deficiency market. They collectively account for maximum market share as of 2021. Market players are employing organic and inorganic growth strategies to expand their foothold in this competitive market.
Some of these companies are investing heavily towards product research and development along with collaborating with other industries to pool resources and expertise and strengthen their product portfolio for personalized treatments.
For instance, Genome institute collaborated with University of California, University of Berkeley, and UC San Francisco for development of CRISPR test. In March 2021, they received the Food and Drug Administration (FDA) approval for their CRISPR test to rectify genetic defects related with sickle cell disease.
Bioverge launched its equity crowd-funding platform called “Bioverge Portal” in April 2021. This platform is designed to assist professional investors in investing into treatments from private healthcare startups.
In November 2020, Mustang Bio Inc. signed a joint agreement with Minaris Regenerative medicine to share technology for research on MB-107 lentiviral gene therapy for X-linked severe combined immunodeficiency and GMP production.
Key players operating in the combined immune deficiency (CID) market are
- LFB SA
- Shire plc
- Kedrion Biopharma Inc
- CSL Behring
- Octapharma
- China Biologic Products Holdings, Inc
- Sanquin,
- Grifols, S.A
- Biotest AG,
- Baxter International Inc.
More Insights on the Combined Immune Deficiency (CID) Market:
Fact MR provides an unbiased analysis of the combined immune deficiency (CID) market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global combined immune deficiency (CID) market with a detailed segmentation on the basis of:
Disease Type
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
Therapy Type
- Immunoglobulin Replacement Therapy
- Bone marrow transplant
- Stem cell transplant
- Lung transplant
- Gene therapy
- Others
End User
- Hospitals
- Ambulatory surgical care
- Research and development institutes
Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Key Questions Covered In the Combined immune deficiency (CID) Market Report
- The report offers insight into combined immune deficiency (CID) demand outlook for 2021-2031
- The market study also highlights projected sales growth for combined immune deficiency (CID) market between 2021 and 2031
- Combined immune deficiency (CID) market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Combined immune deficiency (CID) market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain –
Cancer Immunotherapy Market- Chemotherapy, radiation therapy, and procedures used in traditional cancer treatment have resulted in an unacceptably high percentage of cancer relapse cases. Inadvertently, this is resulting in the development of combination medicines, such as immunotherapy as a first-line cancer treatment. Clinicians are being influenced to focus on giving cancer immunotherapy to patients as the demand for excellent cancer therapies in clinics grows, which is driving the exponential adoption of cancer therapeutics in clinics.
Radioimmunotherapy Market- The market for radioimmunotherapy (RIT) is being propelled by rising acceptance of targeted medicines and an increase in unfavorable radiation therapy consequences. During the forecast period, the global market for radioimmunotherapy (RIT) is likely to be driven by an emerging clinical pipeline of radioimmunotherapy and a focus on innovative treatment strategies for improving patient outcomes. The global radioimmunotherapy (RIT) market is predicted to rise due to an increase in cancer cases and a demand for intensive research and development of cancer therapies.
Immunoglobulins Market- The global immunoglobulins market is expected to grow rapidly, owing to an increase in the prevalence of autoimmune illnesses.
Immunoglobulins are being used more frequently for off-label indications, and this trend is expected to continue. Guillain-Barre Syndrome, multifocal motor neuropathy, dermatomyositis, and stiff person syndrome are all common off-label indications treated with intravenous and subcutaneous immunoglobulins. The continuing new coronavirus pandemic will also benefit the global immunoglobulins market, as healthcare practitioners are conducting extensive research into the use of immunoglobulins in COVID-19 treatment.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR